Business Wire

The Empire State Building Announces New Starbucks Reserve® Sunrise Experience

23.3.2023 17:54:00 EET | Business Wire | Press release

Share

Rise and shine! The Empire State Building (ESB) announced today a brand-new sunrise experience in partnership with the Starbucks Reserve® Empire State Building. The Starbucks Reserve® Sunrise Experience series will kick off April 1 with an early-morning arrival to take in the sunrise from the iconic 86th Floor Observatory, as well as complimentary Starbucks Reserve Empire State Building Microblend Coffee and a specially selected assortment of artisanal Princi® pastries, exclusively by Starbucks Reserve®.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005497/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The 86th Floor Observatory at the Empire State Building; the Empire State Building; an assortment of Princi® pastries and Starbucks Reserve® Empire State Building coffee. (Photo: Business Wire)

“The sunrise experience at the ‘World’s Most Famous Building’ is an unforgettable bucket list experience, made all the more special with our great Starbucks Reserve partners. The sight of daybreak over New York City from the center of it all is just extraordinary,” said Anthony E. Malkin, chairman, president, and CEO of Empire State Realty Trust.

The exclusive Empire State Building Starbucks Reserve® Sunrise Experience is offered every Saturday from April 1 with extremely limited capacity. A reservation is required for the unique opportunity to begin the day on the building’s open-air 86th Floor Observatory. After sunrise time, guests have pre-opening access to the Empire State Building’s immersive museum that chronicles the building’s history from construction to its current place in pop culture.

“We are excited to partner with the Empire State Building to provide a unique experience for our customers and guests to enjoy our exquisite Starbucks Reserve® Empire State Building Microblend Coffee and Princi® pastries while they take in the iconic New York skyline at sunrise,” said Dominic Alessandrini, director of the Starbucks Reserve® Empire State Building store.

The three-floor Starbucks Reserve® store at the base of the Empire State Building offers new, exclusive experiences such as hands-on coffee workshops, guided tasting flights, and an extended artisan menu of new Princi® food only available at this location. More information on the store can be found at starbucksreserve.com/en-us/locations/esb.

The Empire State Building’s world-famous Observatory Experience recently underwent a $165 million reimagination that features an interactive museum with nine galleries, brand-new host uniforms, and iconic Observatories on the 86th and 102nd Floors. The Observatory Experience was recently named #1 attraction in the U.S. – and #3 in the world – in Tripadvisor’s 2022 Travelers’ Choice Best of the Best.

Relevant hi-res imagery can be downloaded here. More information about the Empire State Building and tickets can be found online.

About the Empire State Building
The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience creates an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and was declared "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, the #1 Attraction in the United States in Tripadvisor’s 2022 Travelers’ Choice Best of the Best, and the #1 New York City attraction by Lonely Planet.

Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building's Facebook, Twitter, Instagram, Weibo, YouTube, or TikTok.

About Empire State Realty Trust
Empire State Realty Trust, Inc. (NYSE: ESRT) is a REIT that owns and manages office, retail and multifamily assets in Manhattan and the greater New York metropolitan area. ESRT owns the iconic Empire State Building – the World’s Most Famous Building – and the newly reimagined Empire State Building Observatory that was named #1 attraction in the US, and #3 in the world, in Tripadvisor’s 2022 Travelers’ Choice Awards: Best of the Best. The company is a leader in healthy buildings, energy efficiency, and indoor environmental quality and has the lowest greenhouse gas emissions per square foot of any publicly traded REIT portfolio in New York City. As of Dec. 31, 2022, ESRT's portfolio is comprised of approximately 8.9 million rentable square feet of office space, 741,000 rentable square feet of retail space and 721 residential units across three multifamily properties. More information about Empire State Realty Trust can be found at esrtreit.com and by following ESRT on Facebook, Instagram, Twitter and LinkedIn.

Category: Observatory

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MEDIA CONTACT:

Empire State Realty Trust
Brock Talbot
347-804-7863
btalbot@esrtreit.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye